<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-8909</journal-id>
<journal-title><![CDATA[Medicina crítica (Colegio Mexicano de Medicina Crítica)]]></journal-title>
<abbrev-journal-title><![CDATA[Med. crít. (Col. Mex. Med. Crít.)]]></abbrev-journal-title>
<issn>2448-8909</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Medicina Crítica A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-89092024000700568</article-id>
<article-id pub-id-type="doi">10.35366/119528</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Asociación de los cocientes Soluble fms-like tyrosine kinase 1/Placental Growing Factor + Recuento de plaquetas/volumen plaquetario medio como predictor de resultados adversos en la preeclampsia]]></article-title>
<article-title xml:lang="en"><![CDATA[Association of Soluble fms-like tyrosine kinase 1/Placental Growing Factor + Platelet count/mean platelet volume ratios as a predictor of adverse outcomes in preeclampsia]]></article-title>
<article-title xml:lang="pt"><![CDATA[Associação da relação soluble fms-like tyrosine kinase 1/Placental Growing Factor + Contagem de plaquetas/volume médio de plaquetas como preditor de desfechos adversos na pré-eclâmpsia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gallardo Ramírez]]></surname>
<given-names><![CDATA[Jessica Juve]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Pacheco]]></surname>
<given-names><![CDATA[José Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nares Torices]]></surname>
<given-names><![CDATA[Miguel Ángel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vargas Trujillo]]></surname>
<given-names><![CDATA[Samuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Perinatología «Isidro Espinosa de los Reyes»  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>38</volume>
<numero>7</numero>
<fpage>568</fpage>
<lpage>571</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-89092024000700568&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-89092024000700568&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-89092024000700568&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  el uso de la detección del cociente de desequilibrio entre los factores proangiogénicos/antiangiogénicos (sFlt-1/PlGF) en la sangre materna ha sido una herramienta útil para el diagnóstico de la preeclampsia. La agregación plaquetaria también tiene un papel crucial en el desarrollo de la enfermedad, los parámetros plaquetarios como el cociente recuento de plaquetas/volumen plaquetario medio (PC/MPV) tiene la ventaja de ser fácil, rápido y de bajo costo en la detección de preeclampsia, si sumamos estos cocientes se puede mejorar la capacidad de predicción de la preeclampsia; sin embargo, no hay evidencia sobre el pronóstico y predicción de resultados adversos.  Objetivo:  evaluar la asociación de los cocientes receptor 1 del factor de crecimiento endotelial vascular soluble/factor de crecimiento de la placenta + Recuento de plaquetas/volumen plaquetario medio (sFlt-1/PlGF + PC/MPV) como predictor de resultados adversos en la preclampsia.  Material y métodos:  estudio de descriptivo, retroelectivo, analítico, transversal, unicéntrico, donde se obtuvo información de expedientes electrónicos de las pacientes con diagnóstico de preeclampsia que contaban con mediciones séricas de sFlt-1, PlGF, PC y VPM, se realizó el análisis estadístico de asociación del resultado de la suma de cocientes sFlt-1/PlGF + PC/MPV y los resultados maternos adversos tomando en cuenta lesión renal aguda, eclampsia, complicaciones neurológicas, edema pulmonar, HELLP, lesión hepática, días de estancia en UCIA, uso de terapia sustitutiva de función renal, obito y muerte materna. Se calculó el punto de corte y se utilizó la curva de características operativas del receptor (ROC) para calcular la sensibilidad y especificidad.  Resultados:  se analizaron 57 expedientes de edad entre 15 a 43 años con una media 32 años, encontrando un área bajo la curva (AUC) de 0.768 (IC95%: 0.63-0.90) para el punto de corte de 62.4, sensibilidad de 97.2% y especificidad de 86.7% (p = 0.001) y un riesgo estimado de 4.7 (IC95% 0.40-56.1).  Conclusiones:  la suma de los cocientes sFlt-1/PlGF + PC/MPV, no predice eventos adversos relacionados a complicaciones por preeclampsia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  the use of detection of the ratio of imbalance between proangiogenic/antiangiogenic factors (sFlt-1/PlGF) in maternal blood has been a useful tool for the diagnosis of preeclampsia. Platelet aggregation also plays a crucial role in the development of the disease, platelet parameters such as the ratio platelet count/mean platelet volume (PC/MPV) have the advantage of being easy, fast and low cost in the detection of preeclampsia, if we add these ratios the ability to predict preeclampsia can be improved, however there is no evidence on the prognosis and prediction of adverse outcomes.  Objective:  to evaluate the association of soluble vascular endothelial growth factor receptor 1/placental growth factor + Platelet Count/Mean Platelet Volume (sFlt-1/PlGF + PC/MPV) ratios as a predictor of adverse outcomes in preeclampsia.  Material and methods:  descriptive, retrospective, analytical, cross-sectional, single-center study, where information was obtained from electronic records of patients diagnosed with preeclampsia who had serum measurements of sFlt-1, PlGF, PC and MPV. Statistical analysis of the association of the result of the sum of sFlt-1/PlGF + PC/MPV ratios and adverse maternal outcomes was performed taking into account Acute Kidney Injury, Eclampsia, Neurological Complications, Pulmonary Edema, HELLP, Liver Injury, ICU stay days, use of renal function replacement therapy, Obito and Maternal Death. The cut-off point was calculated and the receiver operating characteristic (ROC) curve was used to calculate sensitivity and specificity.  Results:  57 records were analyzed, with ages ranging from 15 to 43 years with a mean of 32 years, finding an area under the curve (AUC) of 0.768 (95% CI: 0.63-0.90) for the cut-off point of 62.4, sensitivity of 97.2% and specificity of 86.7%, P 0.001 and an estimated risk of 4.7 (95% CI: 0.40-56.1).  Conclusions:  the addition of the sFlt 1/PlGF + PC/MPV ratios does not predict adverse events related to complications from preeclampsia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  o uso da detecção da relação de desequilíbrio entre fatores pró-angiogênicos/antiangiogênicos (sFlt1/PlGF) no sangue materno tem sido uma ferramenta útil para o diagnóstico de pré-eclâmpsia. A agregação plaquetária também tem um papel crucial no desenvolvimento da doença. Os parâmetros plaquetários, como a relação contagem de plaquetas/volume médio de plaquetas (PC/VPM), têm a vantagem de serem fáceis, rápidos e de baixo custo na detecção da pré-eclâmpsia, se somarmos essas proporções podemos melhorar a capacidade de prever a pré-eclâmpsia, porém não há evidências sobre o prognóstico e predição de resultados adversos.  Objetivo:  avaliar a associação das relações receptor 1 do fator de crescimento endotelial vascular solúvel/fator de crescimento placentário + contagem de plaquetas/volume plaquetário médio (sFlt1/PlGF + PC/VPM) como preditor de desfechos adversos na pré-eclâmpsia.  Material e métodos:  estudo descritivo, retroeletivo, analítico, transversal, unicêntrico, onde foram obtidas informações de prontuários eletrônicos de pacientes com diagnóstico de pré-eclâmpsia que realizaram dosagens séricas de sFlt-1, PlGF, PC e VPM, a análise foi realizada estatística de associação do resultado da soma das razões sFlt-1/PlGF + PC/VPM e os resultados maternos adversos, tendo em conta a Lesão Renal Aguda, Eclâmpsia, Complicações Neurológicas, Edema Pulmonar, HELLP, Lesão Hepática, Dias na UTI, utilização de terapêutica de substituição da função renal, Obito e Morte Materna. O ponto de corte foi calculado e a curva ROC (receiver operating characteristic) foi utilizada para calcular a sensibilidade e a especificidade.  Resultados:  foram analisados 57 prontuários com idade entre 15 e 43 anos com média de 32 anos, encontrando-se área sob a curva (AUC) de 0.768 (IC95%: 0.63-0.90) para o ponto de corte de 62.4, sensibilidade de 97.2% e especificidade de 86.7% (p = 0.001) e risco estimado de 4.7 (IC95% 0.40-56.1).  Conclusões:  a soma das razões sFlt1/PlGF + PC/VPM não prediz eventos adversos relacionados a complicações decorrentes da pré-eclâmpsia.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[preeclampsia]]></kwd>
<kwd lng="es"><![CDATA[sFlt1]]></kwd>
<kwd lng="es"><![CDATA[PlGF]]></kwd>
<kwd lng="es"><![CDATA[angiogénicos]]></kwd>
<kwd lng="es"><![CDATA[volumen plaquetario medio]]></kwd>
<kwd lng="en"><![CDATA[preeclampsia]]></kwd>
<kwd lng="en"><![CDATA[sFlt1]]></kwd>
<kwd lng="en"><![CDATA[PlGF]]></kwd>
<kwd lng="en"><![CDATA[angiogenic]]></kwd>
<kwd lng="en"><![CDATA[mean platelet volume]]></kwd>
<kwd lng="pt"><![CDATA[pré-eclâmpsia]]></kwd>
<kwd lng="pt"><![CDATA[sFlt1]]></kwd>
<kwd lng="pt"><![CDATA[PlGF]]></kwd>
<kwd lng="pt"><![CDATA[angiogênico]]></kwd>
<kwd lng="pt"><![CDATA[volume plaquetário médio]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<source><![CDATA[Detección, Diagnóstico y Tratamiento de Enfermedades Hipertensivas del Embarazo. Guía de Evidencias y Recomendaciones: Guía de Práctica Clínica]]></source>
<year>2017</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[IMSS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[WHO Recommendations for prevention and treatment of pre-eclampsia and eclampsia]]></source>
<year>2011</year>
<page-range>1-38</page-range><publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Pacheco]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Espino-y Sosa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Figueroa-Damián]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Preeclampsia-eclampsia, hemorragia postparto y sepsis obstétrica]]></source>
<year>2019</year>
<edition>2da</edition>
<page-range>7</page-range><publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Intersistemas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sibai]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Dekker]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kupferminc]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pre-eclampsia]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2005</year>
<volume>365</volume>
<numero>9461</numero>
<issue>9461</issue>
<page-range>785-99</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magee]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolaides]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[von Dadelszen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preeclampsia]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2022</year>
<volume>386</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1817-32</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serra]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Scazzocchio]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Meler]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nolla]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sabria]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new model for screening for early-onset preeclampsia]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2020</year>
<volume>222</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>608.e1-608.e18</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dimitriadis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rolnik]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Estrada-Gutierrez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Koga]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Francisco]]></surname>
<given-names><![CDATA[RPV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pre-eclampsia]]></article-title>
<source><![CDATA[Nat Rev Dis Primer]]></source>
<year>2023</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maski]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Bajracharya]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wenger]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Salahuddin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology and mechanisms of de novo and persistent hypertension in the postpartum period]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2015</year>
<volume>132</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1726-33</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zeisler]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Llurba]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Chantraine]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Vatish]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Staff]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Sennstrom]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>374</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-22</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cerdeira]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Sullivan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ohuma]]></surname>
<given-names><![CDATA[EO]]></given-names>
</name>
<name>
<surname><![CDATA[Harrington]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Szafranski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized interventional study on prediction of preeclampsia/eclampsia in women with suspected preeclampsia: INSPIRE]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2019</year>
<volume>74</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>983-90</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dragan]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Georgiou]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Prodan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Akolekar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolaides]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks&#8217; gestation]]></article-title>
<source><![CDATA[Ultrasound Obstet Gynecol]]></source>
<year>2017</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>73-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campello]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Spiezia]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Radu]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Dhima]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Visentin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Valle]]></surname>
<given-names><![CDATA[FD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Circulating microparticles in umbilical cord blood in normal pregnancy and pregnancy with preeclampsia]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>2015</year>
<volume>136</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>427-31</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stepan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hund]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Andraczek]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combining biomarkers to predict pregnancy complications and redefine preeclampsia: the angiogenic-placental syndrome]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2020</year>
<volume>75</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>918-26</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Niu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies]]></article-title>
<source><![CDATA[Arch Gynecol Obstet]]></source>
<year>2015</year>
<volume>292</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>507-18</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Shu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Tong]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The expression of serum sEGFR, sFlt-1, sEndoglin and PLGF in preeclampsia]]></article-title>
<source><![CDATA[Pregnancy Hypertens]]></source>
<year>2018</year>
<volume>13</volume>
<page-range>127-32</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lecarpentier]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tsatsaris]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Angiogenic balance (sFlt-1/PlGF) and preeclampsia]]></article-title>
<source><![CDATA[Ann Endocrinol (Paris)]]></source>
<year>2016</year>
<volume>77</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>97-100</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[AlSheeha]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Alaboudi]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Alghasham]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Iqbal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Adam]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Platelet count and platelet indices in women with preeclampsia]]></article-title>
<source><![CDATA[Vasc Health Risk Manag]]></source>
<year>2016</year>
<volume>12</volume>
<page-range>477-80</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lv]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The clinical value of platelet parameters combined with sFlt-1/PlGF in predicting preeclampsia]]></article-title>
<source><![CDATA[Ann Palliat Med]]></source>
<year>2021</year>
<volume>10</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>7619-26</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Castaldi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Acuña]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Marcadores hematológicos predictores de preeclampsia con datos de severidad]]></article-title>
<source><![CDATA[Perinatol Reprod Hum]]></source>
<year>2022</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>33-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
